A Phase 3 Clinical Study of KHK4827

An Extension Study in Subjects With Plaque Psoriasis

This study is designed to evaluate safety and efficacy of long-term exposure of KHK4827 in subjects with moderate to severe plaque psoriasis who have completed the preceding Study 4827-002.

Inclusion Criteria:

• Subject has voluntarily signed the written informed consent form to participate in this study
• Subject has completed the week 12 evaluation of Study 4827-002

Exclusion Criteria:

• Subject has had a serious infection, defined as requiring systemic treatment with antibiotics or antivirals (excluding oral administration)
• Subject has been judged to be ineligible for participation in the study by the investigators/subinvestigators